Company intelligence / Profile preview

Journey Clinical

New York City, New York, United States

Ownership: Private
Employees: ~28
Development stage: Other

Overview

Journey Clinical operates the largest US network enabling ketamine-assisted psychotherapy (KAP) through a collaborative care model linking patients, licensed therapists, and prescribers. As of 2024, it is collaborating with Compass Pathways to inform practical models for future psilocybin delivery, should regulatory approval be obtained. No proprietary clinical trials of therapeutics are sponsored by Journey Clinical itself; it provides infrastructure, clinical coordination, and safe access to evidence-based psychedelic-assisted care.

Therapeutic areas: Psychiatry
Modalities: Small moleculeNon-pharmacological therapy
Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

Compass Pathways (psilocybin research and delivery model)

Beyond the preview

Go deeper on Journey Clinical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Journey Clinical.

Explore the full profile